Posts in Uncategorized

Parallel Exports and Medicine Shortages in Greece: The Proposals on the Table

At PHARMA point 2026 in Thessaloniki on 10–11 October, pharmacy representatives linked medicine shortages in Greece to parallel exports and called for tighter controls. These[…]

The Critical Medicines Act: What the May 2026 Political Agreement Means for Supply Resilience

On 12 May 2026 the European Parliament and the Council reached a provisional agreement on the Critical Medicines Act. EMA welcomed it as a step[…]

Shortage Prevention Plans and Notification Duties: Preparing for the New EU Rules

The reformed EU pharmaceutical legislation tightens obligations around shortages, while EMA is expanding the European Shortages Monitoring Platform. Companies should treat shortage management as a[…]

Member State Supply Requests Under the EU Pharma Package: A New Obligation to Launch

Under the reformed EU pharmaceutical legislation, Member States will be able to ask holders of products with market protection to place them on the national[…]

Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four

The reform of EU pharmaceutical law reshapes market exclusivity for orphan medicines. Published analyses of the final compromise describe a modulated system in place of[…]

Regulatory Data and Market Protection Under the New EU Pharma Package

One of the most closely watched parts of the EU pharmaceutical reform is how long innovators are protected from generic and biosimilar competition. Published legal[…]

The EU Pharma Package: Where the Reform Stands and What the Calendar Looks Like

The reform of EU pharmaceutical legislation has moved from negotiation to implementation planning. Published analyses report that the Council adopted the texts in autumn 2026,[…]

Precautionary Batch Withdrawals: Recall Readiness for Marketing Authorisation Holders

When PRAC reviewed immunoglobulin hypersensitivity reports in October 2026, batches of several products had already been withdrawn as a precaution in certain Member States. The[…]

Deanxit and Article 31 Referrals: How a Safety Review Reaches National Products

PRAC has started a review of Deanxit (flupentixol/melitracen) after reports of movement disorders and memory and thinking problems, some of which persisted after treatment stopped.[…]

PRAC Reviews Immunoglobulin Hypersensitivity Reports: Batch Signals in Practice

At its 26–29 October 2026 meeting, PRAC started a review of increased reports of hypersensitivity reactions with human normal immunoglobulin medicines, linked to specific batches.[…]

1 … 3 4 5 6 7 … 26